Brazil: Automatic cancellation of Cannabis Products’ authorizations by Anvisa: incentive or setback?

Anvisa’s (the Brazilian FDA) regulation for Cannabis Products, Rule #327/2019, provides that, until the end of the 5-year period of their respective authorizations (Article 8), companies must seek approval as a drug, under penalty of automatic cancellation of the authorization (Article 74). The opinion of Anvisa’s Director Fernando Mendes, issued at the time Rule #327/2019[1] […]